Company news

CareDx, Inc. news in 2024

CareDx, Inc.'s news releases, calls and decks from 2024, newest first.

View company

CareDx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

December 17, 2024

CareDx Partners with TC BioPharm to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy

December 10, 2024

CareDx Reports Third Quarter 2024 Results and Raises Revenue Guidance

November 3, 2024

CareDx and Dovetail Genomics Announce Strategic Partnership to Drive Next Wave of Innovation in Transplant Matching with Cutting-Edge Hi-C Technology

October 22, 2024

CareDx Showcases Latest Advancements Across its HLA Typing Solutions at Annual American Society for Histocompatibility and Immunogenetics Meeting

October 20, 2024

CareDx Reports Preliminary Financial Results for Third Quarter 2024

October 14, 2024

CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 10, 2024

CareDx Appoints Jing Huang Chief Data and AI Officer

October 8, 2024

CareDx to Host Investor Day on October 15, 2024

October 7, 2024

CareDx Announces Closure of DOJ Investigation with No Finding of Wrongdoing

October 7, 2024

CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 12, 2024

CareDx Appoints Keith Kennedy Chief Operating Officer and Jessica Meng Chief Commercial Officer

September 11, 2024

CareDx Announces Transplant Community Secures Win Reaffirming Longstanding Medicare Coverage for AlloSure and AlloMap Testing

August 15, 2024

CareDx Reports Second Quarter 2024 Results and Increases Revenue Guidance

July 30, 2024

CareDx to Report Second Quarter 2024 Financial Results

July 15, 2024

Landmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable Patients

June 2, 2024

AI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant Congress

May 29, 2024

CareDx Reiterates Position that it Does Not Infringe the ‘544 Patent, Injunction Motion is Irrelevant

May 28, 2024

Landmark Study Shows CareDx’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies

May 15, 2024

CareDx Reports First Quarter 2024 Results

May 8, 2024

CareDx Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 2, 2024

CareDx to Report First Quarter 2024 Financial Results

April 28, 2024

CareDx Appoints John W. Hanna as its New President and Chief Executive Officer

April 15, 2024

CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting

April 8, 2024

CareDx Appoints Bryan Riggsbee to Its Board of Directors

March 10, 2024

CareDx Announces Fourth Quarter and Full Year 2023 Financial Results

February 27, 2024

CareDx to Participate in the Raymond James & Associates’ 45th Annual Institutional Investors Conference

February 26, 2024

CareDx to Report Fourth Quarter and Full Year 2023 Financial Results

February 20, 2024

CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings

February 20, 2024

CareDx Issues Statement in Patent Infringement Case

January 25, 2024

CareDx Adds to AlloSure Kidney and HeartCare Utility and Clinical Data at 2024 American Society of Transplant Surgeons Winter Symposium

January 10, 2024

CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2023

January 8, 2024

Calls in 2024

Decks in 2024